5KC Stock Chart & Stats
€0.20
€0.09(20.09%)
At close: 4:00 PM EST
€0.20
€0.09(20.09%)
Day’s Range― - ―
52-Week Range€0.09 - €0.25
Previous CloseN/A
Volume2.28K
Average Volume (3M)0.00
Market Cap
€9.33M
Enterprise Value€42.98
Total Cash (Recent Filing)€15.90M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.27
Next Earnings
Feb 25, 2027EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.45
Shares Outstanding45,682,120
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.37
Price to Book (P/B)4.82
Price to Sales (P/S)63.25
P/FCF Ratio-7.76
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.03
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetThe absence of debt limits interest obligations and refinancing exposure, giving PILA greater financial flexibility during development. This cleaner capital structure can help preserve resources for advancing its drug candidate and reduce the risk that lenders constrain strategic choices.
Metabolic Disease FocusA focused strategy around metabolic disease gives the company a clear therapeutic direction and concentrates scarce development resources. Type 2 diabetes is an established treatment area, while a targeted portfolio may help management build expertise around a defined medical and commercial opportunity.
Oral Drug CandidateAn oral small-molecule approach could offer a convenient administration format if development succeeds, supporting potential patient adoption and commercialization. The product also provides a defined lead asset around which PILA can organize future clinical, partnering, and development efforts.
Bears Say
Widening Net LossesWidening losses show that PILA has not yet achieved operating leverage and remains dependent on future financing or successful development outcomes. Continued deficits can erode financial resources and limit the company’s ability to fund research without dilution or other external support.
Persistent Cash BurnOngoing negative operating and free cash flow indicates that the business is consuming capital rather than funding development internally. Unless losses narrow materially, PILA may need continued external funding, which could increase financing risk and reduce flexibility over the next several quarters.
Limited Commercial ScaleSmall, volatile revenue provides little evidence of a durable commercial base or predictable operating funding. The rebound in 2025 followed earlier declines, so PILA remains exposed to development execution and the uncertain timing of future product or partnering revenue.
5KC FAQ
What was PILA PHARMA AB’s price range in the past 12 months?
PILA PHARMA AB lowest stock price was €0.09 and its highest was €0.25 in the past 12 months.
What is PILA PHARMA AB’s market cap?
PILA PHARMA AB’s market cap is €9.33M.
When is PILA PHARMA AB’s upcoming earnings report date?
PILA PHARMA AB’s upcoming earnings report date is Feb 25, 2027 which is in 164 days.
How were PILA PHARMA AB’s earnings last quarter?
PILA PHARMA AB released its earnings results on Aug 27, 2026. The company reported -€0.007 earnings per share for the quarter, beating the consensus estimate of -€0.02 by €0.013.
Is PILA PHARMA AB overvalued?
According to Wall Street analysts PILA PHARMA AB’s price is currently Overvalued.
Does PILA PHARMA AB pay dividends?
PILA PHARMA AB does not currently pay dividends.
What is PILA PHARMA AB’s EPS estimate?
PILA PHARMA AB’s EPS estimate is >-0.01.
How many shares outstanding does PILA PHARMA AB have?
PILA PHARMA AB has 45,682,120 shares outstanding.
What happened to PILA PHARMA AB’s price movement after its last earnings report?
PILA PHARMA AB reported an EPS of -€0.007 in its last earnings report, beating expectations of -€0.02. Following the earnings report the stock price went down -7.971%.
Which hedge fund is a major shareholder of PILA PHARMA AB?
Currently, no hedge funds are holding shares in DE:5KC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PILA PHARMA AB
Based in Sweden, PILA PHARMA AB (publ) is a pharmaceutical firm actively engaged in clinical development. The company's principal drug, XEN-D0501, is a TRPV1 antagonist which has successfully completed two phase 2a clinical studies aimed at treating type 2 diabetes. PILA PHARMA AB (publ) was founded in 2014 and maintains its headquarters in Malmö, Sweden.